Compare Stocks → $16T Crypto Plot From Elon Musk (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:PEPGNASDAQ:SRPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePEPGPepGen$17.25-1.3%$14.08$3.72▼$18.38$559.19M1.7674,777 shs49,204 shsSRPTSarepta Therapeutics$122.84-1.7%$125.38$55.25▼$146.68$11.61B0.962.20 million shs1.00 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePEPGPepGen-1.32%+4.10%+24.82%+11.72%+41.39%SRPTSarepta Therapeutics-1.73%-0.39%-7.29%-0.17%-5.81%Top 5 Tech Stocks to Buy for 2024 (Ad)The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024",MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPEPGPepGen1.8377 of 5 stars3.53.00.00.01.81.70.6SRPTSarepta Therapeutics4.805 of 5 stars4.42.00.04.23.32.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePEPGPepGen3.00Buy$23.0033.33% UpsideSRPTSarepta Therapeutics2.80Moderate Buy$164.0033.51% UpsideCurrent Analyst RatingsLatest PEPG and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/14/2024SRPTSarepta TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$170.00 ➝ $170.005/31/2024SRPTSarepta TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$157.005/28/2024SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$157.00 ➝ $142.005/20/2024SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$166.005/17/2024SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$145.00 ➝ $179.005/15/2024PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.005/15/2024PEPGPepGenWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.005/14/2024SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$180.005/3/2024SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$177.00 ➝ $175.005/2/2024SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$128.005/2/2024SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$166.00(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ASRPTSarepta Therapeutics$1.24B9.34N/AN/A$9.19 per share13.37Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePEPGPepGen-$78.63M-$3.25N/AN/AN/AN/A-57.32%-46.14%8/13/2024 (Estimated)SRPTSarepta Therapeutics-$535.98M$0.111,116.7315.02N/A1.20%2.20%0.58%8/7/2024 (Estimated)Latest PEPG and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024PEPGPepGen-$0.74-$0.63+$0.11-$0.63N/AN/A5/1/2024Q1 24SRPTSarepta Therapeutics-$0.11$0.73+$0.84$0.39$375.52 million$413.50 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPEPGPepGenN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPEPGPepGenN/A15.7815.78SRPTSarepta Therapeutics1.184.053.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPEPGPepGen58.01%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipPEPGPepGen4.60%SRPTSarepta Therapeutics7.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionablePEPGPepGen6432.42 million30.93 millionNot OptionableSRPTSarepta Therapeutics1,31494.52 million87.25 millionOptionablePEPG and SRPT HeadlinesRecent News About These CompaniesJune 15 at 1:42 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Moderate Buy" from BrokeragesJune 14 at 12:29 PM | marketbeat.comSarepta Therapeutics' (SRPT) "Outperform" Rating Reiterated at BMO Capital MarketsJune 14 at 5:14 AM | marketbeat.comBoxer Capital LLC Buys 50,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)June 13 at 4:04 PM | investors.comSarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 TestJune 13 at 1:41 PM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Great Point Partners LLCJune 13 at 12:52 PM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 4.2%June 12 at 3:50 PM | marketbeat.comADAR1 Capital Management LLC Buys Shares of 8,062 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)June 11, 2024 | marketbeat.com75,696 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Capital Fund Management S.A.June 10, 2024 | marketbeat.comAvoro Capital Advisors LLC Increases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)June 7, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 4.1%June 7, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Hsbc Holdings PLCJune 6, 2024 | investorplace.comExit Strategy: 3 Overvalued Stocks to Sell Before They DeflateJune 5, 2024 | marketbeat.comCapital International Investors Purchases 2,917,797 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)June 2, 2024 | marketbeat.comAlpha DNA Investment Management LLC Purchases Shares of 5,832 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 31, 2024 | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 27,549 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 30, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up to $116.25May 30, 2024 | invezz.comSarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?May 29, 2024 | ca.finance.yahoo.comI:RUT Oct 2024 Weekly 2200.000May 29, 2024 | ca.finance.yahoo.comI:RUT Jun 2024 Weekly 1685.000May 29, 2024 | msn.comWith FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And RewardNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsPepGenNASDAQ:PEPGPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Sarepta TherapeuticsNASDAQ:SRPTSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.